20208-73-5

Basic information

• Product Name: N-(1-oxobutyl)glycine
• Synonyms: N-(1-oxobutyl)glycine;2-butanoylaminoacetic acid;N-Butyrylglycine;Butyroyl glycine;Butyrylglycine;Einecs 243-599-6;N-Butanoylglycine;N-n-Butyrylglycine-d2
• CAS NO: 20208-73-5
• Molecular Formula: C₆H₁₁NO₃
• Molecular Weight: 145.15644
• EINECS: 243-599-6
• Product Categories: Amino Acids & Derivatives, Diagnostic, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 20208-73-5.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 379.4°C at 760 mmHg
• Flash Point: 183.2°C
• Appearance: /
• Density: 1.132g/cm³
• Vapor Pressure: 8.36E-07mmHg at 25°C
• Refractive Index: 1.459
• Storage Temp.: Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: N-(1-oxobutyl)glycine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(1-oxobutyl)glycine(20208-73-5)
• EPA Substance Registry System: N-(1-oxobutyl)glycine(20208-73-5)

Safety Data

• Hazardous Substances Data: 20208-73-5(Hazardous Substances Data)

Usage

Description

N-(1-oxobutyl)glycine, also known as Butyrylglycine, is a derivative of glycine, an amino acid, where the carboxy group of butyric acid is formally condensed with the amino group of glycine. It is a part of the acylglycines, an important class of metabolites.

Uses

Used in Diagnostics:
N-(1-oxobutyl)glycine is used as a diagnostic marker for inborn errors of metabolism (IEM). Its presence in biological samples can help identify and monitor various metabolic disorders.
Used in Pharmaceutical Industry:
N-(1-oxobutyl)glycine is used as an intermediate in the synthesis of pharmaceutical compounds. Its unique structure allows for the development of new drugs targeting specific metabolic pathways.
Used in Research:
N-(1-oxobutyl)glycine is used as a research tool to study the role of acylglycines in cellular metabolism and their potential implications in disease processes. This can lead to a better understanding of metabolic disorders and the development of targeted therapies.

InChI:InChI=1/C6H11NO3/c1-2-3-5(8)7-4-6(9)10/h2-4H2,1H3,(H,7,8)(H,9,10)

Upstream product

• 141-75-3 butyryl chloride 
• 56-40-6 glycine 
• 107-92-6 butyric acid 
• 90205-46-2 ethyl 2-butyramidoacetate 
• 106-31-0 butanoic acid anhydride 

Downstream Products

• 1443676-88-7 (Z)-5-(4-hydroxybenzylidene)-3-methyl-2-propyl-3,5-dihydro-4H-imidazol-4-one 
• 1626437-83-9 N-(3-(1-butyryl-2,4-dioxopyrrolidin-3-ylidene)-3-hydroxypropyl)-4-methylbenzenesulfonamide 
• 1527499-46-2 1-butyryl-3-(1-hydroxy-3-(4-(methylthio)phenyl)propylidene)pyrrolidine-2,4-dione 

Relevant articles and documents

Specificity of -chymotrypsin. Separation of polar, steric, and specific effects in the -chymotrypsin-catalyzed hydrolysis of acyl-substituted p-nitrophenyl esters.

-

A Convenient Protocol for the Synthesis of Fatty Acid Amides

Several classes of biologically occurring fatty acid amides have been reported from mammalian and plant sources. Many amides conjugated with fatty acids of mammalian origin exhibit specific activation of individual receptors. Their potential as pharmacological tools or as lead compounds towards the development of novel therapeutics is of great interest. Hence, access to such amides by a practical, high-yielding and scalable protocol without affecting the geometry or position of sensitive functionalities is needed. A protocol that meets all these requirements involves activation of the corresponding acid with carbonyl diimidazole (CDI) followed by reaction with the desired amine or its hydrochloride. More than fifty compounds have been prepared in generally high yields.

Agonists for Antimicrobial Peptide Systems

Short chain fatty acids (SCFAs) and glycerol esters of SCFAs not previously used for that purpose are provided for use as a medicament for treating, preventing or counteracting microbial infections in animals, including humans, by stimulating the innate antimicrobial peptide defense system. Preferred compounds include phenyl substituted short chain fatty acids (SCFAs) derivatives and. Also provided are methods and compositions for treating, preventing or counteracting microbial infections, including bacterial, viral, fungal, and parasitic infections, by administration of medicaments comprising a secretagogue-effective amount of the compounds of the invention.